Cerebrolysin in mild-to-moderate Alzheimer's disease: meta-analysis
Short-term cognitive and global signals favoured Cerebrolysin; cognitive effect at 6 months was not statistically significant while global change remained significant.
What this study tells us
This study reviewed or combined evidence from multiple studies. It can show the overall direction of a field, but its conclusion still depends on the quality and relevance of the studies it included.
Patients with mild-to-moderate Alzheimer disease
n=6 RCTs
Short-term cognitive and global signals favoured Cerebrolysin; cognitive effect at 6 months was not statistically significant while global change remained significant.
Older trials; potential sponsor/author involvement; results differ across cognitive vs global endpoints and from stroke evidence.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Short-term cognitive and global signals favoured Cerebrolysin; cognitive effect at 6 months was not statistically significant while global change remained significant.